Amarin hopes to win over your heart. The company is focused on the development of new drugs to treat cardiovascular diseases. Its lead (and only) candidate, AMR101, is in late-stage clinical trials for the treatment high triglycerides which are a common risk-factor for coronary artery disease. Amarin intends to partner with a larger pharmaceutical firm to commercialize AMR101 in the US and other territories if and when it receives FDA approval. The company's ability to generate revenue hinges upon it getting AMR101 or another candidate to market. Amarin is headquartered in Ireland, but has a research facility in Mystic, Connecticut.